Literature DB >> 29428310

Assessing access to assisted reproductive services for serodiscordant couples with human immunodeficiency virus infection.

Ashley A Leech1, Pietro Bortoletto2, Cindy Christiansen3, Mari-Lynn Drainoni4, Benjamin P Linas5, Cassandra Roeca2, Megan Curtis6, Meg Sullivan5.   

Abstract

OBJECTIVE: To understand the barriers that serodiscordant couples with human immunodeficiency virus (HIV) face in accessing services for risk reduction and infertility using assisted reproductive technology (ART).
DESIGN: Two-arm cross-sectional telephone "secret shopper" study.
SETTING: Infertility clinics designated by the Society for Assisted Reproductive Technology (SART), 140 from 15 American states with the highest prevalence of heterosexual HIV-infected men. PATIENT(S): Clinical and nonclinical staff at SART-registered clinics. INTERVENTION(S): Standardized telephone calls to SART-registered clinics by investigators in the roles of physician and patient callers. MAIN OUTCOME MEASURE(S): Availability and difference in services offered to callers and the rate of referral if the clinic did not provide these services. RESULT(S): Of the 140 sampled SART clinics across 15 states, callers in both patient and physician roles spoke to a staff member at greater than 90% of targeted clinics (127 clinics total). Of the physician callers 63% were told that the clinic could offer services, as compared to 40% of patient callers. Of the 55 clinics that were unable to provide services to the patient caller, 51% referred to other clinics with confidence that they could offer these services; 67% of clinics would provide services for both prevention and infertility purposes. CONCLUSION(S): Risk reduction services for HIV were more available at the sampled fertility clinics than previously reported in the literature. However, the responses depended on the person calling. The clinics demonstrated low rates of concordance with the American Society for Reproductive Medicine's guidelines, which endorse referral of patients to other facilities from sites unable to offer services.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assisted reproduction; HIV prevention; fertility; risk reduction; serodiscordant couples

Mesh:

Year:  2018        PMID: 29428310     DOI: 10.1016/j.fertnstert.2017.11.039

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.490


  5 in total

1.  Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Authors:  Ashley A Leech; James F Burgess; Meg Sullivan; Wendy Kuohung; Michal Horný; Mari-Lynn Drainoni; Cindy L Christiansen; Benjamin P Linas
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

2.  Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers.

Authors:  Mari-Lynn Drainoni; Dea L Biancarelli; Ashley A Leech; Meg Sullivan; Angela R Bazzi
Journal:  J Health Dispar Res Pract       Date:  2018

3.  HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study.

Authors:  Ashley A Leech; Dea Biancarelli; Erika Aaron; Emily S Miller; Jenell S Coleman; Peter L Anderson; Hervette Nkwihoreze; Brianne Condron; Meg Sullivan
Journal:  AIDS Patient Care STDS       Date:  2020-07       Impact factor: 5.078

4.  Successful Pregnancy and Delivery with Intracytoplasmic Sperm Injection in HIV-Serodiscordant Couple: the First Case in Korea.

Authors:  Ji Su Seong; Hoon Kim; Wan Beom Park; Nam Joong Kim; Myoung Don Oh; Sung Sup Park; Joong Shin Park; Young Min Choi
Journal:  J Korean Med Sci       Date:  2020-06-29       Impact factor: 2.153

Review 5.  Medically assisted reproduction for people living with HIV in Europe: A cross-country exploratory policy comparison.

Authors:  Megan H Andersen; Madison T Alexander; Corinne Bintz; Colin Ford; Mallorie Mitchem; Alice Pham; Lily Silverman; Rachel Irwin
Journal:  HIV Med       Date:  2022-03-22       Impact factor: 3.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.